Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso

The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.

Sage Therapeutics Inc. announced a substantial workforce reduction after market close on 7 April, cutting 340 positions, or 53% of its workforce, to reduce spending as it sets out on a new Phase III development plan for zuranolone. The employee reductions will save $170m annually, the firm said.

It's a disappointing turn of events for the newly commercial biopharma, which launched Zulresso (brexanolone) for postpartum depression last year. (Also see "Zulresso Is Sage’s First Step In Postpartum Depression Treatment" - Scrip, 20 March, 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.